Timothy C. Dec - 22 Feb 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Senior Vice-President & CFO
Signature
/s/ Timothy C. Dec
Issuer symbol
SUPN
Transactions as of
22 Feb 2025
Net transactions value
$0
Form type
4
Filing time
24 Feb 2025, 20:16:54 UTC
Previous filing
21 Feb 2025
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Award $0 +500 +6.2% $0.000000 8,591 22 Feb 2025 Direct
transaction SUPN Common Stock Award $0 +3,000 +35% $0.000000 11,591 22 Feb 2025 Direct
transaction SUPN Common Stock Award $0 +2,500 +22% $0.000000 14,091 23 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -500 -50% $0.000000 500 22 Feb 2025 Common Stock 500 Direct F1, F2
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -3,000 -25% $0.000000 9,000 22 Feb 2025 Common Stock 3,000 Direct F1, F3
transaction SUPN Restricted Stock Unit Disposed to Issuer $0 -2,500 -33% $0.000000 5,000 23 Feb 2025 Common Stock 2,500 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F2 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023.
F3 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
F4 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.